Latest News & Features
Africa
‘Technological intelligence’ is very important for extracting maximum value from technology transfer deals, and life sciences companies should use it to their advantage, says Montserrat González-Álvarez of Leyva, Montenegro, Trigueros Abogados. 14 October 2016
Big Pharma
The EU General Court’s decision in September to fine Lundbeck nearly €150 million over several pay-for-delay deals will encourage the European Commission to take further action against similar agreements, say Bernd Allekotte and Franz Zimmer of Grünecker. 14 October 2016
Big Pharma
Pfizer has lost a battle against Actavis in a second medical use patent case centring on the drug Lyrica. 13 October 2016
Big Pharma
The English High Court has ruled on a competition case between NHS England and Servier, holding that Servier should be granted permission to re-amend its defence. 13 October 2016
Biotechnology
New legislation in Brazil aims to create a balance between using genetic resources for scientific advancement and spreading the benefits among local communities fairly, as Gabriel Di Blasi of Di Blasi, Parente & Associados and Eduardo Emrich of Biominas Brasil explain. 13 October 2016
Big Pharma
The UK government must ensure that the vital market for orphan drugs will continue to prosper following Brexit, says Kei Enomoto of Maucher Jenkins. 13 October 2016
Americas
The US Food and Drug Administration has released a final rule to reduce unnecessary litigation between brand owners and generic drugs producers. 12 October 2016
Asia
India-based Piramal Enterprises has signed an agreement with Belgian pharmaceutical company Janssen under which Piramal will acquire five anaesthesia and pain management products for $155 million in cash. 12 October 2016
Americas
Global companies are watching a pending life sciences patent case at the US Supreme Court because of its potential impact both within and outside US borders, as Sandra Kuzmich and Russell Garman of Frommer Lawrence & Haug explain. 12 October 2016
Africa
In a world where research projects are increasingly carried out by several parties in different countries, companies should consider a number of IP-related issues before embarking on multiterritorial collaborations, say Oliver Laing and Tony Proctor of Potter Clarkson. 12 October 2016